Abzena has signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, a Taiwanese biopharmaceutical company. The licensing agreement is for Abzena’s novel site-specific ThioBridge antibody drug conjugate (ADC) linker technology to develop OBI’s proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer. ThioBridge links antibodies and other proteins to drugs. The technology platform is unique in its ability to maintain th...